Research and Markets: Traumatic Brain Injury Therapeutics – Pipeline Assessment and Market Forecasts to 2019

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/g38nbz/traumatic_brain_in) has announced the addition of GlobalData's new report "Traumatic Brain Injury Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.

Need for Further Research into Brain Injuries Creates Opportunities for Pharma.

Opportunities exist for pharmaceutical companies to increase their offerings in the traumatic brain injury (TBI) market, as current therapeutic options for TBI patients are not efficient enough to greatly reduce mortality or prevent brain damage, according to a new report released by healthcare intelligence experts GlobalData.

The new report* suggests that limited funding for new TBI therapies may be hindering the development of effective medicines to counter the increasing number of injuries and fatalities being caused by falls, car accidents and incidences of violence.

The TBI market is a vital part of emergency medicine, requiring therapies that reduce fatalities and prevent further brain damage to reduce resulting disabilities.

While increasingly stringent road safety, fire-arm and alcohol consumption laws, and advancements in automation technology hope to reduce the number of serious accidents taking place, TBI remains a major cause of death and disability in the general population. In the US, one third of all injury related deaths are due to TBI, while an estimated 5.3 million people are living with a permanent TBI-related disability.

Currently, no drug is approved to directly treat any phase of TBI or the associated medical complications. TBI treatment is presently divided into acute management of medical complications in hospitals, treatment for mild TBI symptoms, and management of post-TBI medical complications. The acute management of TBI in hospitals includes treatment for high Intracranial Pressure (ICP), infection prophylaxis, Deep Vein Thrombosis (DVT), hematoma and the prevention of early seizures, with various drugs being employed for the management of each specific complication.

Companies Mentioned

- BHR Pharma, LLC

Read the original:
Research and Markets: Traumatic Brain Injury Therapeutics - Pipeline Assessment and Market Forecasts to 2019